These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 30747340)

  • 1. Cognitive Behavioral Therapy for Treatment-Related Fatigue in Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitors: A Mixed-Method Study.
    Poort H; Onghena P; Abrahams HJG; Jim HSL; Jacobsen PB; Blijlevens NMA; Knoop H
    J Clin Psychol Med Settings; 2019 Dec; 26(4):440-448. PubMed ID: 30747340
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Internet-assisted cognitive behavioral intervention for targeted therapy-related fatigue in chronic myeloid leukemia: Results from a pilot randomized trial.
    Jim HSL; Hyland KA; Nelson AM; Pinilla-Ibarz J; Sweet K; Gielissen M; Bulls H; Hoogland AI; Jacobsen PB; Knoop H
    Cancer; 2020 Jan; 126(1):174-180. PubMed ID: 31553815
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Fatigue Perpetuating Factors as Mediators of Change in a Cognitive Behavioral Intervention for Targeted Therapy-Related Fatigue in Chronic Myeloid Leukemia: A Pilot Study.
    Hyland KA; Nelson AM; Eisel SL; Hoogland AI; Ibarz-Pinilla J; Sweet K; Jacobsen PB; Knoop H; Jim HSL
    Ann Behav Med; 2022 Feb; 56(2):137-145. PubMed ID: 33991085
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correlates of fatigue severity in patients with chronic myeloid leukemia treated with targeted therapy.
    Oswald LB; Hyland KA; Eisel SL; Hoogland AI; Knoop H; Nelson AM; Pinilla-Ibarz J; Sweet K; Jacobsen PB; Jim HSL
    Support Care Cancer; 2022 Jan; 30(1):87-94. PubMed ID: 34231041
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.
    Efficace F; Castagnetti F; Martino B; Breccia M; D'Adda M; Angelucci E; Stagno F; Cottone F; Malato A; Trabacchi E; Capalbo SF; Gobbi M; Visani G; Salvucci M; Capodanno I; Tosi P; Tiribelli M; Scortechini AR; Levato L; Maino E; Binotto G; Gugliotta G; Vignetti M; Baccarani M; Rosti G
    Cancer; 2018 May; 124(10):2228-2237. PubMed ID: 29499087
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adapting an Evidence-Based Intervention to Address Targeted Therapy-Related Fatigue in Chronic Myeloid Leukemia Patients.
    Poort H; Meade CD; Knoop H; Gielissen MFM; Pinilla-Ibarz J; Jacobsen PB
    Cancer Nurs; 2018; 41(1):E28-E37. PubMed ID: 27832018
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Health-related quality of life during bosutinib (SKI-606) therapy in patients with advanced chronic myeloid leukemia after imatinib failure.
    Whiteley J; Reisman A; Shapiro M; Cortes J; Cella D
    Curr Med Res Opin; 2016 Aug; 32(8):1325-34. PubMed ID: 27045164
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Which health-related quality of life aspects are important to patients with chronic myeloid leukemia receiving targeted therapies and to health care professionals? GIMEMA and EORTC Quality of Life Group.
    Efficace F; Breccia M; Saussele S; Kossak-Roth U; Cardoni A; Caocci G; Chie W; Naeem A; Nicolatou-Galitis O; Cocks K; Vignetti M; Baccarani M; Mandelli F; Sprangers M
    Ann Hematol; 2012 Sep; 91(9):1371-81. PubMed ID: 22543826
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fatigue in chronic myeloid leukemia patients on tyrosine kinase inhibitor therapy: predictors and the relationship with physical activity.
    Janssen L; Blijlevens NMA; Drissen MMCM; Bakker EA; Nuijten MAH; Janssen JJWM; Timmers S; Hopman MTE
    Haematologica; 2021 Jul; 106(7):1876-1882. PubMed ID: 32616528
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of tyrosine kinase inhibitors for chronic myeloid leukemia: management of patients and practical applications for pharmacy practitioners.
    Wong SF; Mirshahidi H
    Ann Pharmacother; 2011 Jun; 45(6):787-97. PubMed ID: 21672900
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of Adherence-enhancing Interventions on Adherence to Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukemia (TAKE-IT): A Quasi-experimental Pre-Post Intervention Multicenter Pilot Study.
    Leader A; Benyamini N; Gafter-Gvili A; Dreyer J; Calvarysky B; Amitai A; Yarchovsky-Dolberg O; Sharf G; Tousset E; Caspi O; Ellis M; Levi I; De Geest S; Raanani P
    Clin Lymphoma Myeloma Leuk; 2018 Nov; 18(11):e449-e461. PubMed ID: 30030034
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Variables associated with patient-reported outcomes in persons with chronic myeloid leukemia receiving tyrosine kinase-inhibitor therapy.
    Jiang Q; Wang HB; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2017 Jun; 143(6):1013-1022. PubMed ID: 28251350
    [TBL] [Abstract][Full Text] [Related]  

  • 13. BCR-ABL kinase domain mutations in tyrosine kinase inhibitors-naïve and -exposed Southeast Asian chronic myeloid leukemia patients.
    Wongboonma W; Thongnoppakhun W; Auewarakul CU
    Exp Mol Pathol; 2012 Apr; 92(2):259-65. PubMed ID: 22314255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Patients' and hematologists' concerns regarding tyrosine kinase-inhibitor therapy in chronic myeloid leukemia.
    Jiang Q; Yu L; Gale RP
    J Cancer Res Clin Oncol; 2018 Apr; 144(4):735-741. PubMed ID: 29380058
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ponatinib: A new tyrosine kinase inhibitor for the treatment of chronic myeloid leukemia and Philadelphia chromosome-positive acute lymphoblastic leukemia.
    Shamroe CL; Comeau JM
    Ann Pharmacother; 2013 Nov; 47(11):1540-6. PubMed ID: 24265264
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of Age on NK Cell Compartment in Chronic Myeloid Leukemia Patients Treated With Tyrosine Kinase Inhibitors.
    Rodrigues-Santos P; López-Sejas N; Almeida JS; Ruzičková L; Couceiro P; Alves V; Campos C; Alonso C; Tarazona R; Freitas-Tavares P; Solana R; Santos-Rosa M
    Front Immunol; 2018; 9():2587. PubMed ID: 30487792
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Graded activity is an important component in cognitive behavioral therapy to reduce severe fatigue: results of a pragmatic crossover trial in cancer survivors.
    Abrahams HJG; Gielissen MFM; Braamse AMJ; Bleijenberg G; Buffart LM; Knoop H
    Acta Oncol; 2019 Dec; 58(12):1692-1698. PubMed ID: 31524020
    [No Abstract]   [Full Text] [Related]  

  • 18. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
    Steinberg M
    Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relationship between Carnitine Deficiency and Tyrosine Kinase Inhibitor Use in Patients with Chronic Myeloid Leukemia.
    Iriyama N; Miura K; Uchino Y; Takahashi H; Nakagawa M; Iizuka K; Hamada T; Koike T; Kurihara K; Nakayama T; Takei M; Hatta Y; Nakamura H
    Chemotherapy; 2022; 67(2):96-101. PubMed ID: 34839292
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions.
    Schoenbeck KL; Flynn KE
    Curr Hematol Malig Rep; 2021 Dec; 16(6):491-499. PubMed ID: 34648119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.